[Featured Stock] Nivec, Increased Anticancer Effect and Extended Survival with Combination Peptide Lung Cancer Treatment

[Asia Economy Reporter Hyungsoo Park] Nivek is showing strong performance. The announcement that its developing anticancer drug reduced tumor size by more than 90% appears to have influenced its stock price.

As of 10:30 AM on the 13th, Nivek is trading at 44,000 KRW, up 19.08% from the previous day.

At the JP Morgan Healthcare Conference, Nivek announced research results showing that its anticancer drug under development with global big pharma demonstrated efficacy by reducing tumor size by over 90%.

Nivek confirmed not only excellent efficacy but also high safety in allograft animal model experiments of the anticancer drug. The 'allograft tumor model' is a more advanced experimental stage than conventional verification tests. Nivek verified the safety and efficacy of the anticancer drug targeting 'mutated K-RAS,' known as a major cause of cancer cell proliferation.

Based on its drug delivery platform, Nivek conducted efficacy studies applying the allograft animal model to its self-developed 'peptide-fused K-RAS inhibitor therapy.' The study results showed that compared to the untreated animal control group, tumor size decreased by more than 90%, and survival was extended by up to about 35 days compared to the control group that died within 40 days, verifying outstanding anticancer effects.

Additionally, a single intravenous injection maintained efficacy for about 48 hours without observed side effects from the administered drug. This verified effective drug delivery capability and excellent targeting ability, where the drug is delivered only to the targeted organ without entering other body organs. This suggests that the anticancer drug under development can exhibit greater efficacy not only as a monotherapy but also when combined with existing anticancer agents.

An official stated, "Nivek confirmed that the administered drug was present in lung cancer tissue in the allograft tumor model, proving that the selective drug delivery of its drug delivery platform NIPEP-TPP is applicable to actual lung cancer."

He added, "By confirming tumor size reduction and survival rate in actual lung cancer induced in animal lungs, global big pharma is paying attention to the allograft model results. Based on the experimental results, joint research with global big pharma is expected to gain momentum."